1. Membrane Transporter/Ion Channel
  2. GLUT

GLUT

GLUTs (Glucose transporters ) are proteins comprising 12 membrane-spanning regions. GLUTs transport glucose across the plasma membrane by means of a facilitated diffusion mechanism.

GLUT1 (SLC2A1), a uniporter protein, facilitates the transport of glucose across the plasma membranes of mammalian cells. GLUT2 (SLC2A2) is a transmembrane carrier protein that enables protein facilitated glucose movement across cell membranes. GLUT3 (SLC2A3), mainly present in the brain, has high affinity for glucose. GLUT3 facilitates the transport of glucose across the plasma membranes of mammalian cells. GLUT4 (SLC2A4) is found in the heart, skeletal muscle, adipose tissue, and brain. GLUT4 is an insulin-responsive glucose transporter.

GLUT Related Products (77):

Cat. No. Product Name Effect Purity
  • HY-145597
    KL-11743 Inhibitor 99.40%
    KL-11743 is a potent, orally active, and glucose-competitive inhibitor of the class I glucose transporters, with IC50s of 115, 137, 90, and 68 nM for GLUT1, GLUT2, GLUT3, and GLUT4, respectively. KL-11743 specifically blocks glucose metabolism. KL-11743 can synergize with electron transport inhibitors to induce cell death. In addition, KL-11743 can induce the formation of disulfide bonds in actin cytoskeletal proteins, leading to the occurrence of cellular disulfidptosis[1][2][3][4].
  • HY-19331
    WZB117 Inhibitor 99.93%
    WZB117 is a glucose transporter 1 (Glut1) inhibitor, which downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo.
  • HY-N0142
    Phloretin Inhibitor 99.92%
    Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill.,has anti-inflammatory activities. Phloridzin is a specific,competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC50values of 49 μM and 61 μM,respectively[1].Phloretin has the potential for the treatment of rheumatoid arthritis (RA) and allergic airway inflammation[4].
  • HY-100017
    BAY-876 Inhibitor
    BAY-876 is an orally active and selective glucose transporter 1 (GLUT1) inhibitor with an IC50 of 2 nM. BAY-876 is >130-fold more selective for GLUT1 than GLUT2, GLUT3, and GLUT4. BAY-876 is also a potent blocker of glycolytic metabolism and ovarian cancer growth. In addition, BAY-876 can induce the formation of disulfide bonds in actin cytoskeletal proteins, leading to the occurrence of cellular disulfidptosis[1][2][3].
  • HY-18728
    STF-31 Inhibitor 99.79%
    STF-31 is a selective inhibitor of glucose transporter 1 (GLUT1), with an IC50 of 1 μM. STF-31 is also a NAMPT inhibitor. STF-31 inhibits glucose uptake in renal cell carcinoma (RCC) 4 cells[1][2].
  • HY-167857S
    Glutathione Disulfide-13C4,15N2
    Glutathione Disulfide-13C4,15N2 is the 13C- and 15N-labeled (Rac)-Glutipyran (HY-167857). (Rac)-Glutipyran is a broad-spectrum GLUT inhibitor that targets both GLUT1 and GLUT3. (Rac)-Glutipyran inhibits glucose uptake and suppresses the growth of multiple cancer cells, significantly inhibiting PANC-1 cell growth (IC50=1.8 μM) and glucose uptake (IC50=0.13 μM)[1].
  • HY-174145
    GLUT4 activator 3 Modulator
    GLUT4 activator 3 (Compound 13a) is an antidiabetic agent targeting GLUT4 translocation in skeletal muscle. GLUT4 activator 3 can promote the translocation of glucose transporter 4 (GLUT4) in skeletal muscle cells. GLUT4 activator 3 reduces blood glucose in STZ-induced diabetic rats[1].
  • HY-174377
    PeS-9 Activator

    PeS-9 is an Androgen Receptor (AR) degrader that induces androgen receptor degradation PeS-9 induces mitochondrial and ER stress by promoting cytotoxic ROS production, leading to the release of mitochondrial cytochrome C and AIF. PeS-9 subsequently activates caspases-9 and -3, causing DNA fragmentation and apoptotic cell death. PeS-9 has anticancer activity against prostate cancer and exerts in vivo antitumor and antimetastatic activity with minor side effects. PeS-9 can be used for the study of targeting monotherapy against GLUT-1-overexpressing tumors[1].

  • HY-139066
    Punicic acid Agonist
    Punicic acid is a bioactive compound of pomegranate seed oil. Punicic acid is an isomer of conjugated α-linolenic acid and ω-5 polyunsaturated fatty acids. Punicic acid has anti-inflammatory and antioxidant activities and can inhibit the expression of inflammatory mediators such as tumor necrosis factor α (TNF-α). Punicic acid can also reduce the formation of β-amyloid deposits and hyperphosphorylation of tau by increasing the expression of GLUT4 protein and inhibiting the overactivation of calpain, and is used to prevent and treat neurodegenerative diseases. In addition, punicic acid also has breast cancer inhibitor properties that depend on lipid peroxidation and PKC pathways[1][2][3][4].
  • HY-145963
    DRB18 Inhibitor 99.58%
    DRB18 is a potent pan-class GLUT inhibitor. DRB18 alters energy-related metabolism in A549 cells by changing the abundance of metabolites in glucose-related pathways. DRB18 can eventually lead to G1/S phase arrest and increase oxidative stress and necrotic cell death. DRB18 has anti-tumor activity[1].
  • HY-148315
    GLUT1-IN-2 Inhibitor 99.27%
    GLUT1-IN-2 (compound 17) is a GLUT1 inhibitor with an IC50 value of 12 μM. GLUT1-IN-2 shows inhibitory effect to Plasmodium falciparum hexose transporter PfHT with an IC50 value of 13 μM. GLUT1-IN-2 can be used for the research of infection[1].
  • HY-125062
    Steviolmonoside 99.87%
    Steviolmonoside (Glucosilsteviol) is a structural analogue of steviol. Steviolmonoside decreases glucose production and inhibits oxygen uptake in rat renal cortical tubules[1].
  • HY-N0142R
    Phloretin (Standard) Inhibitor
    Phloretin (Standard) is the analytical standard of Phloretin. This product is intended for research and analytical applications. Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill., has anti-inflammatory activities. Phloridzin is a specific, competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC50values of 49 μM and 61 μM, respectively[1].Phloretin has the potential for the treatment of rheumatoid arthritis (RA) and allergic airway inflammation[4].
  • HY-128361
    SLC26A3-IN-3 Inhibitor
    SLC26A3-IN-3 (compound 4az) is a SLC26A3 inhibitor (IC50: 40 nM). SLC26A3-IN-3 can be used for research of constipation, cystic fibrosis[1].
  • HY-W110888
    Brilliant Yellow Inhibitor
    Brilliant Yellow, a diazo-containing sulfonic aci, is also a potent VGLUT-specific inhibitor. Brilliant Yellow is membrane-impermeable. However, there are some Brilliant Yellow analogs with low cytotoxicity and cell penetration. Brilliant Yellow analogs work on glutamatergic transmission in hippocampal neurons[1].
  • HY-N0668
    Rubusoside Inhibitor
    Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase)[1][2][3][4].
  • HY-158056
    URAT1/GLUT9-IN-1 Inhibitor
    URAT1/GLUT9-IN-1 (compound 29) can inhibit both uric acid transporter 1 (URAT1) (IC50=2.01 μM) and glucose transporter 9 (GLUT9) (IC50=18.21 μM). URAT1/GLUT9-IN-1 exhibits favorable pharmacokinetic properties and oral bioavailability. URAT1/GLUT9-IN-1 can be uesd for gout and hyperuricemia research[1].
  • HY-163726
    GLUT1/EGFR-IN-1 Inhibitor 99.75%
    GLUT1/EGFR-IN-1 (compound H) is a potent inhibitor of GLUT1 and EGFR. GLUT1/EGFR-IN-1 can simultaneously act on the EGFR tyrosine kinase ATP-binding site and inhibit GLUT1-mediated energy metabolism, resulting in reductions in ATP, MMP, intra-cellular lactic acid, and EGFR nuclear transfer. GLUT1/EGFR-IN-1 can be used for nasopharyngeal carcinoma (NPC) and triple-negative breast cancer (TNBC) research[1].
  • HY-101849
    Fasentin Inhibitor
    Fasentin, a potent glucose uptake inhibitor, inhibits GLUT-1/GLUT-4 transporters. Fasentin preferentially inhibits GLUT4 (IC50=68 μM) over GLUT1. Fasentin is a death receptor stimuli (FAS) sensitizer and sensitizes cells to FAS-induced cell death. Fasentin is also a tumor necrosis factor (TNF) apoptosis-inducing ligand sensitizer. Fasentin blocks glucose uptake in cancer cell lines and has anti-angiogenic activity[1][2][3].
  • HY-163139
    Physagulide Y Inhibitor
    Physagulide Y (2), a withanolide with anticancer activity, is a GLUT1 inhibitor[1].